Health technologies are reshaping healthcare, opening up new ways to care for patients, diagnose conditions earlier, and help people stay healthier for longer. From wearables to A ...

This guidance has been updated and replaced by NICE technology appraisal guidance 939 ...

NICE has been working in partnership with the London School of Economics and Political Science (LSE) to jointly develop and deliver an Executive MSc in Healthcare Decision-Making. Discover how this ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

DMD Care UK's guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations: NICE review NG251 5 September 2025 5 September 2025 ...

NICE is currently consulting on updated evaluation methods through October 2025, working with industry and healthcare partners to refine the assessment framework. The programme will initially focus on ...

NICE is unable to make a recommendation on mirabegron (Betmiga) for treating neurogenic detrusor activity in people 3 to 17 years. This is because the company did not provide an evidence submission.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance. We've worked with Public Health England (PHE) to bring together our information on managing ...

There are commercial access agreements for enfortumab vedotin and pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...